share_log

Nexgel (NXGL) Sees Recovery On US Stock Charts Following Record Quarterly Revenue

Nexgel (NXGL) Sees Recovery On US Stock Charts Following Record Quarterly Revenue

Nexgel(NXGL)在创纪录的季度营业收入后,在美国股票图表上看到复苏
Stocks Telegraph ·  07/09 01:15

Shares of Nexgel, Inc. (NASDAQ: NXGL) experienced a notable recovery on the US stock charts following the market close on Monday, driven by record revenue figures. During the after-market session, NXGL stock surged by 17.16% to reach $2.39, recovering from a regular-session loss of -7.69%.

根据市场的最新营业收入数据,Nexgel公司(纳斯达克代码:NXGL)在周一收盘后在美国股票交易市场上经历了显著的复苏,股票价格大涨17.16%,达到2.39美元,恢复了常规交易会议中的-7.69%的损失。

Table of Contents

目录

Toggle
切换
  • Quarterly Revenue of
  • Nexgel
  • Future Outlook
  • Strategic Partnership with Cintas Corporation
  • Nexgel营业收入季报
  • Nexgel
  • 未来展望
  • Cintas公司战略合作伙伴关系

Quarterly Revenue of

Nexgel营业收入季报

Nexgel

Nexgel

Nexgel announced its preliminary, unaudited revenue for the second quarter of 2024 and provided revenue guidance for the third and fourth quarters of the same year. According to the preliminary data, Nexgel reported a second-quarter revenue of $1.4 million, marking an approximate 20% increase year-over-year and a 10% sequential growth.

Nexgel宣布其第二季度的初步未经审计营业收入,并提供同年第三季度和第四季度的营业收入指导。根据初步数据,Nexgel报告第二季度营业收入达140万美元,同比增长约20%,环比增长10%。

The company also anticipates a significant year-over-year increase of 83% in Q3 2024, projecting revenues of $2.2 million. Nexgel anticipates growth in the second half of this year, which puts the firm in a strong position to transition to positive cash flow from operations, even if the Q3 estimate does not yet include any revenue from its collaboration with AbbVie.

该公司还预计,2024年第三季度年同比营业收入将大幅增长83%,预计营业收入为220万美元。Nexgel预计在今年下半年实现增长,这将使该公司处于强劲的转正现金流的位置,即使第三季度的估计尚未包括其与AbbVie公司的合作的任何营业收入。

Future Outlook

未来展望

Despite facing lower-than-normal revenues at CG Converting and Packaging due to a move into a newly expanded facility, Nexgel delivered record revenue for the second quarter of 2024. The company provided an optimistic outlook for the second half of the year, surpassing expectations for both contract manufacturing and consumer products. The growth in contract manufacturing is attributed primarily to new customer relationships with large global corporations, while several NXGL brands are also experiencing substantial growth.

尽管由于进入新的扩建工厂而导致CG Converting and Packaging收入低于正常水平,但Nexgel公司仍然在2024年第二季度实现了创纪录的营业收入。该公司对下半年的前景持乐观态度,超过了合同制造和消费品的预期。合同制造的增长主要归因于与大型全球公司的新客户关系,而几个NXGL品牌也在经历着实质性的增长。

Strategic Partnership with Cintas Corporation

Cintas公司战略合作伙伴关系

In a strategic business move, Nexgel announced a supply agreement with Cintas Corporation, a leading provider of corporate identity uniforms, first aid and safety products, and services to over one million businesses across North America. Through this partnership, Cintas will distribute SilverSeal, a hospital-grade hydrogel dressing for wounds and burns, to its customers across various sectors, including hospitality and public service.

在一项战略性的商业举措中,Nexgel宣布与Cintas Corporation签订了供应协议,Cintas Corporation是北美领先的企业身份制服、急救和安全用品以及服务的供应商,向万家企业提供服务。通过这一合作伙伴关系,Cintas将向其客户分销SilverSeal,一种医用级别的水凝胶敷贴,用于治疗创伤和烧伤,包括酒店和公共服务等各种领域。

NXGL expects the first order of SilverSeal to be delivered during the fourth quarter of 2024. This partnership is significant for Nexgel, not only for the associated revenue but also for enhancing brand awareness of SilverSeal.

NXGL预计SilverSeal的第一笔订单将在2024年第四季度交付。这一合作伙伴关系对Nexgel来说非常重要,不仅因为其相关的营业收入,而且还因为增强了SilverSeal品牌的知名度。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发